Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02029495 · ClinicalTrials.gov registry record · Phase 3
Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis
A Phase 3 study, sponsored by Bausch Health Americas.
- Terminated
- Registry status
- Phase 3
- Development phase
- 478
- Enrollment target
NCT02029495 is a Phase 3 study that was terminated before completion, run by Bausch Health Americas. The registered enrollment target is 478 participants.
The verdict
NCT02029495, a Phase 3 study, was terminated before completion, sponsored by Bausch Health Americas.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 478 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis.
Interventions
- DRUG Placebo
- DRUG 210 mg brodalumab
- DRUG 140 mg brodalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 478 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02029495
The ClinicalTrials.gov registry entry for NCT02029495 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 478 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02029495 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02029495 about?
NCT02029495 is a clinical study titled "Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis". The primary objective of this study is to evaluate the efficacy of brodalumab, compared to placebo, in subjects with psoriatic arthritis.
What is the current status of trial NCT02029495?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 478 participants. The study started on 2014-03. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02029495?
The interventions under investigation include: Placebo (DRUG), 210 mg brodalumab (DRUG), 140 mg brodalumab (DRUG).
Who is sponsoring clinical trial NCT02029495?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.